BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20544508)

  • 1. Limited intra-individual variability in hypoxanthine-Guanine phosphoribosyl transferase, thiopurine S-methyl transferase, and xanthine oxidase activity in inflammatory bowel disease patients during 6-thioguanine therapy.
    van Asseldonk DP; de Boer NK; Smid K; Mulder CJ; van Bodegraven AA; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):284-90. PubMed ID: 20544508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
    Seinen ML; van Asseldonk DP; de Boer NK; Losekoot N; Smid K; Mulder CJ; Bouma G; Peters GJ; van Bodegraven AA
    J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine.
    Jharap B; de Boer N; Vos R; Smid K; Zwiers A; Peters G; Mulder C; Wilhelm A; van Bodegraven A
    Br J Pharmacol; 2011 Jun; 163(4):722-31. PubMed ID: 21323897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series.
    Seinen ML; de Boer NK; Smid K; van Asseldonk DP; Bouma G; van Bodegraven AA; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1085-90. PubMed ID: 22132961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
    Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
    Sanderson J; Ansari A; Marinaki T; Duley J
    Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of thiopurines in inflammatory bowel disease.
    Derijks LJ; Wong DR
    Curr Pharm Des; 2010; 16(2):145-54. PubMed ID: 20205660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
    Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
    Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease.
    Ding L; Zhang FB; Liu H; Gao X; Bi HC; Wang XD; Chen BL; Zhang Y; Zhao LZ; Zhong GP; Hu PJ; Chen MH; Huang M
    Inflamm Bowel Dis; 2012 Jan; 18(1):63-73. PubMed ID: 21381155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic drug monitoring of 6-thioguanine nucleotides in inflammatory bowel disease: interest and limits].
    Jourdil N; Fonrose X; Boulieu R; Stanke-Labesque F;
    Therapie; 2010; 65(3):177-86. PubMed ID: 20699068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
    Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
    Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease.
    Qasim A; McDonald S; Sebastian S; McLoughlin R; Buckley M; O'Connor H; O'Morain C
    Scand J Gastroenterol; 2007 Feb; 42(2):194-9. PubMed ID: 17327939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines.
    Fotoohi AK; Lindqvist M; Peterson C; Albertioni F
    Biochem Biophys Res Commun; 2006 Apr; 343(1):208-15. PubMed ID: 16530731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of inosine-5'-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease.
    Haglund S; Vikingsson S; Söderman J; Hindorf U; Grännö C; Danelius M; Coulthard S; Peterson C; Almer S
    Ther Drug Monit; 2011 Apr; 33(2):200-8. PubMed ID: 21311411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients.
    Almer SH; Hjortswang H; Hindorf U
    Dig Liver Dis; 2009 Mar; 41(3):194-200. PubMed ID: 18799369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
    Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG
    Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.